

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/70, C07H 21/00, C12P 19/34	A1	(11) International Publication Number: WO 99/01139 (43) International Publication Date: 14 January 1999 (14.01.99)
(21) International Application Number: PCT/US98/13711 (22) International Filing Date: 2 July 1998 (02.07.98) (30) Priority Data: 60/051,705 3 July 1997 (03.07.97) US (71) Applicant (for all designated States except US): THOMAS JEFFERSON UNIVERSITY [US/US]; 1020 Locust Street M-60, Philadelphia, PA 19107-6799 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): TU, Guang-Chou [CN/US]; Apartment B-220, 2803 Stanbridge Street, East Norriton, PA 19401 (US). ISRAEL, Yedi [CN/US]; Apartment 303D, 241 South 6th Street, Philadelphia, PA 19106 (US). (74) Agents: LEARY, Kathryn, Doyle et al.; Panitch Schwarze Jacobs & Nadel, P.C., One Commerce Square, 22nd floor, 2005 Market Street, Philadelphia, PA 19103-7086 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: AN IMPROVED METHOD FOR DESIGN AND SELECTION OF EFFICACIOUS ANTISENSE OLIGONUCLEOTIDES		
(57) Abstract The invention includes methods for predicting whether an antisense oligonucleotide (ASO) will be efficacious for inhibiting expression of a gene. The invention also includes methods of making efficacious ASOs, comprising a 5'-TCCC-3' motif or another chemical entity which is capable of Watson-Crick-type base-pairing with a 5'-GGGA-3' motif in an RNA molecule such as a primary transcript or an mRNA. The invention further includes ASOs which are useful for inhibiting expression of one of tumor necrosis factor- α in a mammal. Methods of treating an animal comprising a disease or disorder which is characterized by the presence of an RNA molecule in a cell of the animal are also included.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

AN IMPROVED METHOD FOR DESIGN AND SELECTION OF EFFICACIOUS ANTISENSE OLIGONUCLEOTIDES

FIELD OF THE INVENTION

The field of the invention is antisense oligonucleotides.

5

BACKGROUND OF THE INVENTION

Antisense oligonucleotides (hereinafter, "ASO"s) are short, usually synthetic, nucleic acids designed to bind to mRNA or other nucleic acids comprising specific sequences, taking advantage of Watson-Crick-type base pairing. Prior art ASO therapeutic strategies are designed to suppress the expression of specific genes involved in cancer, inflammatory diseases, and viral infections (Crooke et al., 1996, Annu. Rev. Pharmacol. Toxicol. 36:107-129). More than ten ASOs are currently undergoing human clinical trials for the treatment of various diseases (Matteucci et al., 1996, Nature 384(Supp.):20-22; Agrawal, 1996, Trends Biotechnol. 14: 376-387).

Antisense therapy comprising binding of an ASO to mRNA in a cell affected by a disease or disorder has, to date, been a therapeutic strategy wherein it has been difficult to identify efficacious target sites for a given RNA sequence (Gewirtz et al., 1996, Proc. Natl. Acad. Sci. U.S.A. 93:3161-3163). A significant shortcoming of prior art antisense strategies is the inability to accurately predict which ASOs will prove efficacious among a population of potentially efficacious ASOs (Laptev et al., 1994, Biochemistry 33:11033-11039). Because prior art attempts to predict the therapeutic efficacy of ASOs have been largely unsuccessful, selection of ASO sequences for antisense therapy has, prior to the present disclosure, been performed by empirically screening large numbers of potential antisense agents (Bennett et al., 1994, J. Immunol. 152:3530-3540). Using trial-and-error ASO selection strategies of the prior art, a large number of ASOs must be tested in order to discover a few sequences which exhibit significant efficacy as therapeutic ASOs. Prior art strategies require the

screening of large numbers of ASOs because any portion of an mRNA molecule can be used to design a complementary ASO.

For example, an mRNA molecule which consists of 2000 nucleotide residues affords 1980 potential target sites for an ASO comprising twenty-one nucleotides which is complementary to twenty-one sequential nucleotide residues of the mRNA molecule. The trial-and-error methods of the prior art ASO selection process therefore recommend the manufacture and assay of at least 30-40 potential ASOs in order to identify likely no more than a few efficacious ASOs. Clearly, a method of designing ASOs which reduces or avoids dependence on trial-and-error selection methods would be of great value by reducing the duration and expense of ASO development efforts.

Investigations have been made by others to determine the effect upon efficacy of designing ASOs complementary to various regions of mRNA molecules. In general, these investigations have concentrated on complementation of an ASO to a discrete region within mRNA molecules. For example, various investigators have determined that efficacious ASOs may be constructed which are complementary:

- a) to regions encompassing the 5'-cap site of an mRNA molecule (Ojala et al., 1997, *Antisense Nucl. Drug Dev.* 7:31-38),
- b) to regions encompassing the transcription start site (Monia et al., 1992, *J. Biol. Chem.* 267:19954-19962),
- c) to regions encompassing the translation initiation codon (Dean et al., 1994, *Proc. Natl. Acad. Sci. U.S.A.* 91:11762-11766),
- d) to regions encompassing the translation stop codon (Wang et al., 1995, *Proc. Natl. Acad. Sci. USA* 92:3318-3322),
- e) to regions encompassing sites at which mRNA molecules are spliced (Agrawal et al., 1988, *Proc. Natl. Acad. Sci. U.S.A.* 86:7790-7794; Colige et al., 1993, *Biochem.* 32:7-11),

- f) to regions encompassing the 5'-untranslated region of mRNA molecules (Duff et al., 1995, J. Biol. Chem. 270:7161-7166; Yamagami et al., 1996, Blood 87:2878-2884),
- g) to regions encompassing the 3'-untranslated region of mRNA molecules (Bennett et al., 1994, J. Immunol. 152:3530-3540; Dean et al., 1994, J. Biol. Chem. 269:16146-16424), and
- h) to regions encompassing the coding region (Laptev et al., 1994, Biochem. 33:11033-11039; Yamagami et al., 1996, Blood 87:2878-2884).

Because efficacious ASOs may, as demonstrated by these investigators, be complementary to any region of an mRNA molecule, the ASO designer is not provided any meaningful guidance by these studies.

Several strategies have been proposed to facilitate and simplify the selection process for efficacious ASOs. One strategy relies upon predictions of the binding energy between an ASO and a complementary sequence in an mRNA molecule. Chiang et al. (1991, J. Biol. Chem. 266:18162-18171) designed ten ASOs complementary to mRNA encoding human ICAM-1 protein with the aid of the computer program, OLIGO. These ten oligonucleotides were designed to maximize the melting temperature (T_m) of the oligonucleotide-mRNA complex. However, these investigators discovered that the efficacy of the ASOs as inhibitors of ICAM-1 expression did not correlate directly with either the T_m of the oligonucleotide-mRNA complex or the ΔG°_{37} (change in free energy upon association/dissociation of the oligonucleotide and the mRNA complex, as assessed at 37°C). The most potent oligonucleotide (ISIS 1939) identified by these investigators exhibited a T_m value that was lower than those corresponding to the majority of the other oligonucleotides which were tested. Thus, maximization of binding energy between an ASO and a complementary mRNA is not sufficient to ensure therapeutic efficacy of the oligonucleotide.

Stull et al. (1992, Nucl. Acids Res. 20:3501-3508) investigated a systematic approach for predicting appropriate sequences within an mRNA molecule

against which complementary ASOs could be constructed, by calculating three thermodynamic indices: (i) a secondary structure score (Sscore), (ii) a duplex score (Dscore); and (iii) a competition score (Cscore), which is the difference between the Dscore and the Sscore. The Sscore estimates the strength of local mRNA secondary structures at the mRNA binding site for the ASO. The Dscore estimates $\Delta G_{\text{formation}}$, the change in Gibbs free energy upon formation of the duplex, of the oligonucleotide-mRNA target sequence duplex. These three indices were compared to the efficacy of ASOs for inhibiting protein expression. It was found that the Dscore was the most consistent predictor of ASO efficacy in four of the five studies (the correlation factor r^2 ranged from 0.44 to 0.99 in these four studies). The results of the fifth study could not be predicted by any thermodynamic or physical index.

A second strategy for selecting efficacious ASOs is based upon predicting the secondary structure of mRNA. Wickstrom and colleagues (1991, In Prospects for antisense nucleic acid therapy of cancer and AIDS, Wickstrom, ed., Wiley-Liss, Inc., New York, 7-24) attempted to correlate the efficacy of potential ASOs with the secondary structure of the complementary region of the mRNA. It was hypothesized that ASOs would be the most efficacious when they were designed to be complementary to the target sequences within the mRNA molecule which were the least involved in the secondary and tertiary structure of the mRNA molecule. These investigators designed fourteen ASOs which were complementary to the predicted stems, loops, and bulges of human C-myc p65 mRNA. ASOs were designed which were complementary to regions of the mRNA molecule between the 5'-cap site and the translation initiation codon AUG, and included oligonucleotides which were complementary to sequences located within a predicted hairpin sequence which was located immediately 3' to the AUG initiation codon. These investigators discovered that two fragments, one comprising the 5'-cap sequence and the other comprising a sequence located slightly 3' relative to the cap sequence, were better target sequences for ASOs than the sequence spanning the AUG initiation codon, even though the

sequence spanning the AUG initiation codon was located at an even weaker bulge and stem area.

Lima et al. (1992, Biochem. 31:12055-12061) designed six ASOs, each of which was complementary to a portion of a 47-nucleotide region that was able to achieve a stable hairpin conformation within an activated *Ha-ras* gene transcript. These investigators discovered that two of the oligonucleotides which were complementary to the loop portion of the hairpin structure had nearly equal binding affinity for the transcript. In contrast, they observed that oligonucleotides which were complementary to the double-stranded stem portion of the hairpin structure were less tightly bound, having affinity constants that were smaller by a factor of between 10^5 and 10^6 . These results suggest that mRNA sequences which lie within regions of secondary structure may be undesirable target sequences for designing complementary ASO.

Thierry et al. (1993, Biochem. Biophys. Res. Commun. 190:952-960) compared the efficacy of ASOs which were complementary to either the 5'-end of the coding region of or to a single-stranded loop in the mRNA encoded by the multidrug resistance gene *mdr1*. The results obtained by these investigators indicate that the oligonucleotides targeted to the single-stranded loop were more efficacious and specific than the oligonucleotides targeted to the 5'-end coding region. However, Laptev et al. (1994, Biochem. 33:11033-11039) obtained results which were not consistent with that suggestion. Laptev et al. concluded that the most efficacious ASOs were those which were complementary to mRNA sequences that were predicted to form clustered double-stranded secondary structures.

Still other investigators presented evidence that the most efficacious ASOs (ISIS 1939 and ISIS 2302) were those which were complementary to regions of human ICAM-1 mRNA, which regions were predicted by computer modeling to form stable stem-loop structures (Chiang et al., 1991, J. Biol. Chem. 266:18162-18171; Bennett et al., 1994, J. Immunol. 152:3530-3540). Oligonucleotides which were complementary to mRNA sequences upstream or downstream from these putative

stem-loop structures had significantly less inhibitory activity (Bennett et al., 1994 Adv. Pharmacol. 28:1).

Fenster et al. (1994, Biochemistry 33, 8391-8398) observed that inhibition of gene expression by an ASO was highly dependent upon the position of the mRNA sequence to which the oligonucleotide was complementary. These
5 investigators discovered that the most potent ASOs to effect inhibition of the Rev-response element of the human immunodeficiency virus (HIV) were complementary to mRNA target sites corresponding to the stem-loop V region of the HIV mRNA. This region of the HIV mRNA is known to be important for full and efficient Rev-response
10 element function. ASOs targeted to other, noncritical Rev-response element stem-loops (e.g. SLI and SLIII) were determined by these investigators to be either non-efficacious or 30-fold less efficacious than stem-loop V oligonucleotides for inhibiting Rev-response element function.

Hence, it is clear that the bulk of ASO selection strategies reported in
15 the prior art have been directed to designing ASOs which are complementary to discrete regions within mRNA molecules, rather than to particular sequences within mRNA.

Recently, Ho et al. (1996, Nucl. Acids Res. 24:1901-1907; 1998, Nature
Biotechnol. 16:59-63) developed a novel approach to rationally select ASOs. These
20 investigators contacted an mRNA molecule encoding human multidrug resistance-1 protein and an mRNA molecule encoding angiotensin type I receptor protein with a library of chimeric oligonucleotides. Hybridized mRNA was subsequently treated with RNase H, an enzyme which catalyzes the hydrolytic cleavage of only the RNA strand of an RNA-DNA duplex. The RNA fragments which were generated were sequenced
25 to identify regions on the mRNA sequence which were involved in RNA-DNA duplex formation. Using the sequence information, these investigators constructed ASOs which were complementary to these regions and found those particular ASOs to be significantly more efficacious than randomly-selected oligonucleotides for inhibiting human multidrug resistance-1 protein or angiotensin type I receptor protein expression.

These results demonstrate that it is feasible to construct improved ASOs by incorporating therein sequences which are complementary to particular nucleotide sequences found in mRNA molecules.

5 Skilled workers in the art have concluded the therapeutic efficacy of an ASO which is complementary to a particular target sequence within an mRNA molecule has not heretofore been accurately predictable (Gewirtz et al., 1996, Proc. Natl. Acad. Sci. U.S.A. 93:3161-3163). Because efficacious ASOs have been made which are complementary to most or all regions of mRNA molecules, the ASO designer cannot be meaningfully guided by selection of any particular mRNA region.

10 Methods for predicting the efficacy of ASOs by maximization of T_m or $\Delta G_{\text{formation}}$ have not consistently yielded correct predictions, and thus are similarly of limited use to the ASO designer. Analyses of the secondary structure of an mRNA do not clearly identify potential ASO-binding sites. Library-based RNaseH degradation studies are laborious and complex. Other skilled workers in the art have recognized that a long-

15 felt, but unmet, need exists for methods of selecting the most potent target sequences within a given mRNA sequence (Szoka, 1997, Nature Biotechnol. 15:509).

 In April of 1998, results of a consensus reached at U.S. National Institutes of Health conference on this subject were reported. These results included the conclusions that "[i]t appears that the only way to generate an active oligomer is by

20 brute force" and that "[o]ptimally it is best to screen 30-40 oligos to obtain one species that is maximally active, but this may be impossible because of time and cost considerations" (Stein, 1998, Antisense and Nucleic Acid Drug Development 8: 129-132).

 Taken together, the results of these prior art methods for designing an

25 ASO sequence offer little guidance to the ASO designer. The present invention overcomes the shortcomings of prior art ASO design methods by providing a method for designing efficacious ASOs.

SUMMARY OF THE INVENTION

The invention relates to an antisense oligonucleotide for inhibiting expression of a gene which encodes TNF- α in an animal. The oligonucleotide comprises from 12 to 50 nucleotide residues. At least 90% of the nucleotide residues of this oligonucleotide are complementary to a region of an RNA molecule which corresponds to the gene, and the region comprises a GGGA motif. In one embodiment, the oligonucleotide comprises from 14 to 30 nucleotide residues, comprises a TCCC motif, and at least 95% of the nucleotide residues of the oligonucleotide are complementary to the region. In another embodiment, the oligonucleotide comprises from 16 to 21-nucleotide residues, comprises a TCCC motif, and is completely complementary to the region. Preferably, the oligonucleotide has a nucleotide sequence selected from the group consisting of SEQ ID NOs: 19-27, SEQ ID NOs: 31-33, SEQ ID NOs: 44-55, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 60, and SEQ ID NO: 61. Also preferably, the animal is a human.

The invention also relates to a method of making an antisense oligonucleotide for inhibiting expression of a gene in an animal. This method comprises identifying an RNA molecule corresponding to the gene, wherein the RNA molecule comprises a GGGA motif; and synthesizing an oligonucleotide complementary to at least a portion of the RNA molecule. The portion comprises the GGGA motif. In one embodiment of this method, at least a portion of the oligonucleotide comprises a randomly-generated sequence. In another embodiment, gene is a human gene. In still another embodiment, the RNA molecule is the primary transcript of the gene.

The invention includes an antisense oligonucleotide made by this method.

The invention further relates to a method of treating an animal afflicted with a disease or disorder characterized by the presence in an affected cell of the animal of an RNA molecule which corresponds to a gene and comprises a region comprising a GGGA motif. This method comprises providing an antisense oligonucleotide which is

at least 90% complementary to the region and administering the oligonucleotide to the animal. In one aspect of this method, the antisense oligonucleotide is at least 95% complementary to the region. In a preferred embodiment, the antisense oligonucleotide is completely complementary to the region. In yet another embodiment, the RNA molecule is the primary transcript of the gene. Preferably, the animal is a human and the encodes human TNF- α . In another aspect of this method, at least one linkage between nucleotide residues of the oligonucleotide is a phosphorothioate linkage.

The invention also relates to a method of inhibiting expression of a gene in an animal cell. This method comprises administering to the cell an antisense oligonucleotide which is complementary to a region of an RNA molecule corresponding to the gene, wherein the region comprises a GGGA motif.

The invention includes a method of predicting the efficacy of an antisense oligonucleotide for inhibiting expression of a gene. This method comprises determining whether the antisense oligonucleotide is complementary to a region of an RNA molecule corresponding to the gene, wherein the region comprises a GGGA motif. If so, this is an indication that the antisense oligonucleotide is efficacious for inhibiting expression of the gene.

The invention further relates to a method of separating from a mixture of oligonucleotides an antisense oligonucleotide which is efficacious for inhibiting expression of a gene. This method comprises contacting the mixture with a support linked to an oligonucleotide comprising a GGGA motif, whereby the efficacious antisense oligonucleotide associates with the support, and separating the support from the mixture.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a bar graph which depicts the effect of three different ASOs on the expression of TNF- α by cultured Kupffer cells. Data are reported as a percentage of TNF- α protein expression in control cultures which were not treated with an ASO.

Figure 2 is a bar graph which indicates the inhibition of TNF- α expression achieved by culturing cells in the presence of the indicated ASOs.

Figure 3 is an image which portrays the results of Northern hybridization experiments described herein in Example 4. "Motif containing" refers to whether the ASO used in the corresponding lane comprised a TCCC motif.

Figure 4 is the nucleotide structure of the human TNF- α gene. Nucleotide residues corresponding to GGGA motifs in transcription products encoding TNF- α are indicated with capital letters. Nucleotide residues corresponding to regions of a transcription product which could be used as target sequences for design of efficacious ASO having a length of up to 21 nucleotide residues are underlined.

DETAILED DESCRIPTION

The invention relates to the discovery of a method of designing efficacious ASOs for use in antisense nucleic acid methods including, but not limited to, methods of inhibiting gene expression.

This discovery was made during a study wherein a large number of phosphorothioate-modified ASOs, each comprising from nineteen to twenty-one nucleotide residues, were designed to be complementary to various regions of an RNA molecule which encodes rat TNF- α protein. After screening the ASOs for their ability to inhibit expression of TNF- α , it was observed that only an ASO which was complementary to a fragment in the 3'-untranslated region of the mRNA markedly inhibited (i.e. >90% inhibition) the expression of TNF- α protein by cultured rat Kupffer cells. The gene which specifies this mRNA fragment has been reported (GENBANK DDBJ D00475; NCBI Seq. Id. # 220920). The nucleotide sequence of this gene comprises twenty-eight tetranucleotide 5'-GGGA-3' sequences (hereinafter referred to as "GGGA motifs"). Accordingly, ASOs which were complementary to this sequence had nucleotide sequences which comprised at least one copy of the sequence 5'-TCCC-3' (hereinafter referred to as a "TCCC" motif).

A series of ASOs, each comprising between sixteen and twenty-one nucleotide residues, were designed, synthesized, and screened to determine the efficacy thereof for inhibiting expression of TNF- α protein. It was discovered that most ASOs which were complementary to at least one of the twenty-eight TNF- α GGGA motifs (i.e. any ASO having a nucleotide sequence comprising at least one TCCC motif) displayed high inhibitory efficacy.

It was further discovered that the presence of the TCCC motif in an ASO is an indication that the ASO is efficacious for inhibiting protein expression from genes unrelated to TNF- α .

Because the presence of the GGGA motif in an RNA molecule has not previously been identified as a basis for designing efficacious ASOs, the existence of known efficacious ASOs having sequences comprising a TCCC motif was investigated. The results of a comprehensive search indicated that about half of the most efficacious ASOs which have been reported comprise the TCCC motif. Recognition of the significance of the TCCC motif in efficacious ASOs represents a significant advance over the prior art. The presence of the TCCC motif in an ASO complementary to an RNA molecule is an indication that the ASO will inhibit expression of the protein encoded by the RNA molecule. Thus, the skilled worker presented with either the nucleotide sequence of an RNA molecule or the sequence of a gene encoding an RNA molecule is enabled to design an ASO which will efficaciously inhibit expression of the RNA molecule or gene by designing the ASO to be complementary to that portion of the RNA molecule which comprises a GGGA motif.

Definitions

As used herein, the term "flanking" is used to refer to nucleotide sequences which are directly attached to one another, having no intervening nucleotides. By way of example, the pentanucleotide 5'-AAAAA-3' is flanking the trinucleotide 5'-TTT-3' when the two are connected thus: 5'-AAAAATTT-3' or 5'-TTTAAAAA-3', but not when the two are connected thus: 5'-AAAAACTTT-3'. In the

latter case, the C residue is said to be "interposed" between the pentanucleotide and the trinucleotide.

As used herein, the term "affected cell" refers to a cell in an animal afflicted with a disease or disorder, which affected cell has an altered phenotype relative to a cell of the same type in an animal not afflicted with the disease or disorder.

As used herein, the term "oligonucleotide" means a nucleic acid-containing polymer, such as a DNA polymer, an RNA polymer, or a polymer comprising both deoxyribonucleotide residues and ribonucleotide residues. This term further includes other polymers, such as polymers comprising modified or non-naturally-occurring nucleic acid residues and polymers comprising peptide-nucleic acids. Each of these types of polymers, as well as numerous variants, are known in the art. This term includes, without limitation, both polymers which consist of nucleotide residues, polymers which consist of modified or non-naturally-occurring nucleic acid residues, and polymers which consist of peptide nucleic acid residues, as well as polymers comprising these residues associated with a support or with a targeting molecule, such as a cell surface receptor-binding protein.

As used herein, the term "antisense oligonucleotide" (ASO) means a nucleic acid polymer, at least a portion of which is complementary to a nucleic acid which is present in a normal cell or in an affected cell. The ASOs of the invention preferably comprise from twelve to about fifty nucleotide residues. More preferably, the ASOs comprise from fourteen to about thirty nucleotide residues. Most preferably, the ASOs comprise from sixteen to twenty-one nucleotide residues. The ASOs of the invention include, but are not limited to, phosphorothioate oligonucleotides and other modifications of oligonucleotides.

As used herein, the term "antisense agent" means an ASO suspended in a pharmaceutically acceptable carrier, whereby the ASO can be delivered to a cell of an animal, preferably a human. The term "antisense agent" includes naked DNA ASOs and naked RNA ASOs for delivery to a cell of an animal.

As used herein, the term "antisense therapy" means administration to an animal of an antisense agent for the purpose of alleviating a cause or a symptom of a disease or disorder with which the animal is afflicted.

As used herein, an oligonucleotide "associates" with another oligonucleotide or to a support to which the other oligonucleotide is linked when it binds to the other oligonucleotide in an affinity-dependent manner. By way of example, an oligonucleotide which hydrogen bonds to another oligonucleotide having a complementary nucleotide sequence when contacted therewith is said to associate with a support to which the other oligonucleotide is linked when the oligonucleotide is contacted with the medium.

As used herein, the term "binding energy" means the thermodynamic change in free energy which accompanies the binding of two complementary nucleic acids, one to the other. Binding energy is frequently expressed in terms of a change in the Gibbs free energy (ΔG or $\Delta G_{\text{formation}}$) at a given temperature.

"Complementary" refers to the broad concept of sequence complementarity between regions of two nucleic acid strands or between two regions of the same nucleic acid strand. A first region of a nucleic acid is complementary to a second region of the same or a different nucleic acid if, when the two regions are arranged in an antiparallel fashion, at least one nucleotide residue of the first region is capable of base pairing with a nucleotide residue of the second region. Preferably, when the first and second regions are arranged in an antiparallel fashion, at least about 50%, and preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residues of the first region are capable of base pairing with nucleotide residues in the second region. Most preferably, all nucleotide residues of the first region are capable of base pairing with nucleotide residues in the second region (i.e. the first region is "completely complementary" to the second region). It is known that an adenine residue of a first nucleic acid strand is capable of forming specific hydrogen bonds ("base pairing") with a residue of a second nucleic acid strand which is antiparallel to the first strand if the residue is thymine or uracil. Similarly, it is known

that a cytosine residue of a first nucleic acid strand is capable of base pairing with a residue of a second nucleic acid strand which is antiparallel to the first strand if the residue is guanine. It is understood that structure of nucleotide residues may be modified, whereby the complementation properties of the modified residue differs from the complementation properties of the naturally-occurring residue. Such modifications, and methods of effecting such modification, are known in the art.

As used herein, the term "complementary region of an RNA molecule" means a nucleotide sequence within an RNA molecule to which nucleotide sequence an ASO is complementary.

10. As used herein, an RNA molecule "corresponds" to a gene if the RNA molecule is generated upon transcription of the gene.

As used herein, an RNA molecule includes, without limitation, both the primary transcript ("pre-mRNA") obtained by transcribing a gene and a messenger RNA ("mRNA") obtained by transcribing a gene and processing the primary transcript.

15 As used herein, the term "gene" means a DNA sequence which, upon transcription thereof, yields an RNA molecule which encodes a protein and associated control sequences such as a translation initiation site, a translation stop site, a ribosome binding site, (optionally) introns, and the like. Alternately, the gene may be an RNA sequence which encodes a protein and associated control sequences such as a translation initiation site, a translation stop site, a ribosome binding site, and the like.

20 As used herein, the term "gene expression" includes both gene transcription, whereby DNA (or RNA in the case of some RNA-containing viruses) corresponding to a gene is transcribed to generate an RNA molecule and RNA translation, whereby an RNA molecule is translated to generate a protein encoded by the gene.

25 As used herein, the term "inhibition of gene expression" means inhibition of DNA transcription (or RNA transcription in the case of some RNA-containing viruses), inhibition of RNA translation, inhibition of RNA processing, or some combination of these.

As used herein, the term "oligonucleotide delivery agent" means a composition of matter which can be used to deliver an ASO to a cell *in vitro* or *in vivo*.

As used herein, the term "pharmaceutically-acceptable carrier" means a chemical composition with which an ASO of the invention may be combined and
5 which, following the combination, can be used to administer the ASO of the invention to an animal.

As used herein, the term "protein expression" is used to refer both to gene expression comprising transcription of DNA (or RNA) to form an RNA molecule and subsequent processing and translation of the RNA molecule to form protein and to
10 gene expression comprising translation of mRNA to form protein.

As used herein, the term "TNF- α -associated disease or disorder" means a disease or disorder of an animal which is caused by abnormal TNF- α expression or a disease or disorder which results in abnormal TNF- α expression, wherein abnormal TNF- α expression is determined relative to an animal not afflicted with the disease or
15 disorder.

As used herein, the term "TNF- α -specific ASO" means an ASO which comprises a TCCC motif and which is complementary to an RNA molecule encoding TNF- α .

As used herein, the term "TCCC motif" means a tetranucleotide portion
20 of an ASO, having the sequence 5'-TCCC-3'. It is understood that each of the four nucleotide residues of the TCCC motif may be any chemical entity which exhibits substantially the same complementarity properties as the residue it substitutes. Thus, the term TCCC motif includes any chemical entity which is capable of binding with a GGGA motif with substantially the same complementarity properties as a
25 tetranucleotide portion of an ASO, having the sequence 5'-TCCC-3'.

As used herein, the term "GGGA motif" means a portion of an RNA molecule comprising a tetranucleotide having the sequence 5'-GGGA-3'.

In the context of the present invention, the following abbreviations for the commonly occurring nucleic acid bases are used. "A" refers to adenosine, "C"

refers to cytidine, "G" refers to guanosine, "T" refers to thymidine, and "U" refers to uridine.

The Efficacious ASO of the Invention

5 The invention relates to the surprising discovery that an ASO which comprises a TCCC motif and is complementary to an RNA molecule, such as an mRNA or, preferably, a primary transcript, corresponding to a gene is efficacious for inhibiting expression of the gene. The ASO of the invention is complementary to a region of an RNA molecule corresponding to a gene, wherein the region of the RNA molecule comprises at least one GGGA motif. Also preferably, the ASO comprises not
10 more than one nucleotide which is not complementary to the RNA molecule corresponding to the gene.

The ASO of the invention comprises between about fourteen and about fifty nucleotides. Preferably, the ASO of the invention comprises between about twelve and about thirty nucleotides; even more preferably, it comprises between about
15 sixteen and about twenty-one nucleotides. The invention also features an ASO which comprises at least a pair of flanking nucleotides having a phosphorothioate or other modified (i.e. non-phosphodiester) linkage. The gene may, for example, be a gene of a DNA or RNA virus. Preferably the gene is an animal gene; even more preferably it is a human gene.

20 Oligonucleotides which contain phosphorothioate modification(s) are known to confer upon the oligonucleotide enhanced resistance to nucleases. As many as all of the nucleotide residues of an ASO may be phosphorothioate-modified, as may as few as one residue. Specific examples of modified oligonucleotides include those which contain phosphorothioate, phosphotriester, methyl phosphonate, short chain
25 alkyl or cycloalkyl intersugar linkages, or short chain heteroatomic or heterocyclic intersugar ("backbone") linkages. In addition, oligonucleotides having morpholino backbone structures (U.S. Patent No: 5,034,506) or polyamide backbone structures (Nielsen et al., 1991, Science 254: 1497) may also be used. Oligonucleotides which are methylated or alkylated at the 2' hydroxyl position are also specifically included

herein. These and other modified nucleotide residues, including peptide nucleic acids, for example, are known to those skilled in the art and are useful in the compositions and methods of the invention. Further by way of example, oligonucleotides comprising modified or non-naturally-occurring deoxyribonucleotide residues, modified or non-naturally-occurring ribonucleotide residues, or both, are likewise known and included in the compositions and methods of the invention.

The examples of oligonucleotide modifications described herein are not exhaustive and it is understood that the invention includes additional modifications of the ASOs of the invention which modifications serve to enhance the therapeutic properties of the ASO without appreciable alteration of the basic sequence of the ASO of the invention.

The antisense agents of the present invention may be incorporated in compositions suitable for a variety of modes of administration. One skilled in the art will appreciate that the optimal dose and methodology will vary depending upon the age, size, and condition of an animal. Optimal dose and route of administration are further dependent upon the bodily location of the organ, tissue, or cell to which the antisense agent of the invention is to be administered. Administration is generally continued until the cause or symptom of the disease or disorder is alleviated or cannot be detected.

Predicting the Efficacy of an ASO

The invention also includes a method for predicting whether an ASO will be efficacious for inhibiting expression of a gene, the method comprising determining whether the ASO is complementary to a portion of an RNA molecule corresponding to the gene, wherein that portion comprises a GGGA motif.

Methods of Making the Efficacious ASO of the Invention

The invention further includes a method for making an ASO which is efficacious for inhibiting expression of a gene having a corresponding RNA molecule. Such an ASO is made by synthesizing an oligonucleotide which comprises a TCCC motif and which is complementary to an RNA molecule corresponding to the gene.

Methods for synthesizing an oligonucleotide having a selected nucleotide sequence are well known in the art. By way of example, a nucleotide sequence may be synthesized using an automated nucleotide synthesizing apparatus. The invention also includes, but is not limited to, ASOs made using this method.

5 The invention also includes an additional method of making an ASO which is efficacious for inhibiting expression of a gene having a corresponding RNA molecule which comprises an S_1 GGGAS $_2$ sequence, wherein S_1 is a first RNA nucleotide sequence, and wherein S_2 is a second RNA nucleotide sequence. According to this method, the nucleotide sequence of the gene is obtained and a portion of the
10 gene which encodes an S_1 GGGAS $_2$ sequence in the corresponding RNA molecule is identified. The ASO is made by designing a nucleotide sequence which is complementary to the GGGA portion of the S_1 GGGAS $_2$ sequence and which is also complementary to at least a portion of one of the first RNA nucleotide sequence (i.e. S_1) and to at least a portion of the second RNA nucleotide sequence (i.e. S_2). The
15 invention also includes ASOs made using this method.

Yet another method for making the ASO of the invention comprises making a plurality of ASOs, each of which comprises a TCCC motif and a randomly-generated sequence which flanks the TCCC motif on at least one side of the motif. Methods for synthesizing oligonucleotides comprising random sequences are well
20 known in the art of molecular biology. The screening methods described herein may be used to screen the plurality of oligonucleotides to identify ASOs which are efficacious for inhibiting expression of a gene.

The ASOs of the invention include, but are not limited to, phosphorothioate oligonucleotides and other modifications of oligonucleotides.
25 Methods for synthesizing oligonucleotides, phosphorothioate oligonucleotides, end-group-modified oligonucleotides, and otherwise modified oligonucleotides are known in the art (e.g. U.S. Patent No: 5,034,506; Nielsen et al., 1991, Science 254: 1497).

Methods of Separating the Efficacious ASO from a Mixture of Oligonucleotides

The invention also includes methods of separating an ASO from a mixture of oligonucleotides, wherein the ASO is efficacious for inhibiting expression of a gene having a corresponding RNA molecule. These methods comprise contacting the mixture of oligonucleotides with a support which comprises a polynucleotide linked thereto, the polynucleotide comprising a portion having the sequence GGGA. After contacting the mixture with the support, the support is separated from the mixture, whereby efficacious ASOs remain bound to the support and are separated from the mixture. Various supports known in the art may be linked to the GGGA nucleotide sequence using known methods. By way of example, the sequence may be linked to cross-linked agarose beads or to a solid silica support. The polynucleotide may, for example, be all or a portion of the corresponding RNA molecule or a single strand of DNA having a nucleotide sequence homologous with the sequence of the corresponding RNA molecule.

Better separation of the efficacious ASO may be effected by treating the medium with an agent which causes dissociation of the efficacious ASO from the support. Once again, such agents are well known in the art and depend upon the type of support employed in the method. By way of example, when the support comprises the oligonucleotide comprising a portion which has a GGGA sequence linked to a solid silica matrix, the agent may be heat applied to a solution contacting the support, whereby the efficacious ASO dissociates from the support when the solution reaches the melting temperature of the ASO-oligonucleotide-GGGA sequence complex. Likewise by way of example, when the support is cross-linked agarose beads, agents such as solvents and salts, which interfere with hydrogen bonding between the ASO and the oligonucleotide comprising a portion which has a GGGA sequence, may be used to cause dissociation of the efficacious ASO from the support.

Another method for improving the separation of the efficacious ASO from the mixture comprises performing the methods described herein, and subsequently contacting the oligonucleotide mixture comprising the efficacious ASO

with a second medium which comprises a portion of the corresponding RNA molecule linked to a second support.

Methods of Treating Diseases and Disorders Which are Characterized by the Presence of an RNA Molecule

5 The invention features methods of treating diseases and disorders which are characterized by the presence in affected cells of an animal afflicted with the disease or disorder of an RNA molecule which corresponds to a gene. The RNA molecule may, for example, be one which is normally expressed in cells and expressed at an abnormal level in affected cells, or it may be one which is expressed only in
10 affected cells, for example, one which is expressed only in affected cells by way of infection of the cell or abnormal gene expression in the cell. The molecule may be an mRNA molecule, for example, and is preferably a primary transcript. The methods comprise administering to the cells an antisense agent comprising an ASO of the invention which is efficacious for inhibiting expression of the gene.

15 The ASO may be administered to the animal to deliver a dose of between 1 ng/kg/day and 250 mg/kg/day. Preferably, the dose is between 5 mg/kg/day and 50 mg/kg/day. Antisense agents that are useful in the methods of the invention may be administered systemically in oral solid dosage forms, ophthalmic, suppository, aerosol, topical, intravenously-, intraperitoneally, or subcutaneously-injectable, or other
20 similar dosage forms. In addition to an ASO, such pharmaceutical compositions may contain pharmaceutically acceptable carriers and other ingredients known to enhance and facilitate drug administration. Other possible dosage forms, such as nanoparticles, liposomes, resealed erythrocytes, and immunologically based systems may also be used to administer the antisense agent according to the methods of the invention.

25 Furthermore, antisense agents may be delivered using 'naked DNA' methods, wherein the oligonucleotides are not complexed with a carrier, or using viral vectors, such as adenoviral vectors or retroviral vectors.

 Some examples of diseases and disorders which may be treated according to the methods of the invention are discussed herein. The invention should

not be construed as being limited solely to these examples, as other diseases or disorders which are at present unknown, once known, may also be treatable using the methods of the invention.

Treatment of Inflammatory Diseases

5 The invention also features methods of treating inflammatory diseases which are associated with tumor necrosis factor alpha (TNF- α). TNF- α is a proinflammatory cytokine which exhibits pleiotropic effects on various cell types and tissues both *in vivo* and *in vitro*. Local expression of TNF- α is essential for cell homeostasis, but overexpression of TNF- α has been linked to numerous inflammatory
10 conditions such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, leprosy, septic shock, and inflammatory bowel disease. Various studies have also established that TNF- α levels are greatly elevated in the plasma of humans afflicted with alcoholic hepatitis and cirrhosis, and that high TNF- α levels are correlated with
15 mortality (McClain et al., 1986, Life Sci. 39:1474-1485; Felver et al., 1990 Alcohol. Clin. Exp. Res. 14:255-259; Bird et al., 1990, Ann. Int. Med. 112:917-920; Khoruts et al., 1991, Hepatol. 13:267-276; Sheron et al., 1991, Clin. Exp. Immunol. 84:449-453). Efforts to inhibit or control TNF- α overexpression are useful for the treatment of a number of conditions, including those discussed herein.

 The invention includes a method of inhibiting expression of TNF- α .
20 The method is useful for treating an animal afflicted with a TNF- α -associated disease or disorder. The method comprises administering a composition to an affected cell of an animal afflicted with a TNF- α -associated disease or disorder, which composition comprises an ASO which comprises a TCCC motif and which is complementary to an RNA molecule corresponding to a gene which encodes TNF- α . Preferably, the ASO is
25 selected from the group of ASOs which consists of the ASOs having nucleotide sequences designated SEQ ID NOs: 19-27, SEQ ID NOs: 31-33, SEQ ID NOs: 44-55, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 60, and SEQ ID NO: 61. Given the homology that exists among animal TNF- α (and other) genes, a strategy similar to that

described herein may be employed to design ASOs useful for inhibiting expression of TNF- α (and other) genes in a human.

5 The composition may also comprise an oligonucleotide delivery agent, such as a liposome, a plasmid, a nanoparticle projectile, a viral vector, or the like, for delivering the ASO to the interior of the affected cell. In view of the present disclosure, the skilled artisan is enabled to design ASOs specifically useful in humans using the nucleotide sequence of the human TNF- α gene.

10 For example, the nucleotide sequence of the human TNF- α gene has been described (Nedwin et al., 1985, Nucl. Acids Res. 13:6361; GenBank Accession Nos. X02910 and X02159; Figure-4). By identifying GGGA-motifs in the nucleotide sequence of the primary transcript of the human TNF- α gene, one skilled in the art may design ASOs which are effective for inhibiting expression of the human TNF- α gene by selecting a region of the primary transcript corresponding to the human TNF- α gene, the region having a length of from 12 to 50 nucleotide residues, preferably having
15 a length between 14 and 30 nucleotide residues, and more preferably having a length between 16 and 21 nucleotide residues. The region also comprises a GGGA motif. The efficacious ASO is designed by designing a nucleotide sequence which is at least 90%, preferably at least 95% complementary, and most preferably 100% complementary to the nucleotide sequence of the selected region of the primary
20 transcript. The efficacious ASO may comprise modified or non-naturally-occurring nucleotide residues, whereby the modified or non-naturally-occurring residues are capable of Watson-Crick-type base-pairing with the selected region of the primary transcript. Also preferably, the region of the primary transcript is selected such that it comprises a GGGA motif which is flanked by regions having high purine content or
25 which are otherwise able to assume an A-form conformation.

By way of example, ASOs which are efficacious for inhibiting expression of human TNF- α and which have a length of up to 21 nucleotide residues may be made by synthesizing oligonucleotides which are at least 90%, preferably at least 95%, and most preferably 100% complementary to one of the underlined or

double-underlined regions in Figure 4. Thus, an ASO which is efficacious for inhibiting expression of human TNF- α may have a nucleotide sequence which is complementary to up to, for example, sixteen to twenty-one consecutive nucleotide residues of the regions of the human TNF- α gene listed in Table 1, wherein the ASO is

5 complementary to the GGGA motif in the region.

Table 1

Region Designation	Nucleotide Residues ^A
I	291 - 328
II	367 - 413
III	567 - 603
IV	645 - 682
V	801 - 838
VI	957 - 994
VII	1005 - 1169
VIII	1287 - 1324
IX	1333 - 1370
X	1414 - 1451
XI	1579 - 1616
XII	1695 - 1757
XIII	1900 - 1937
XIV	1967 - 2070
XV	2409 - 2446
XVI	2461 - 2498
XVII	2558 - 2595
XVIII	2865 - 2902
XIX	3090 - 3147
XX	3310 - 3347
XXI	3424 - 3461
XXII	3594 - 3634

Note: ^ANucleotide residues are identified using the numbering scheme used in Figure 4. The indicated regions are inclusive of the nucleotide residues identified as boundaries.

ASOs which are complementary to an mRNA molecule corresponding to a gene and which are efficacious may be designed by an analogous method, wherein the nucleotide sequence of the mRNA molecule is substituted in place of the nucleotide sequence of the primary transcript in the preceding paragraph.

5 Methods of Inhibiting Gene Expression

The invention further features methods of inhibiting the expression of a gene in a cell, which methods comprise administering to the cell an ASO of the invention.

10 When gene expression is to be inhibited in the cell *in vitro*, ordinary transfection techniques are used to effect entry of the oligonucleotide into the cell. When gene expression is to be inhibited in the cell *in vivo*, then the above-described procedures are followed.

15 The invention is now described with reference to the following examples. These examples are provided for the purpose of illustration only and the invention should in no way be construed as being limited to these examples but rather should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.

Examples

20 The materials and methods used in the experiments described in the Examples are now described.

Oligonucleotides

25 All phosphorothioate-modified oligonucleotides used in this study were synthesized and purified by Genset (La Jolla, CA). Prior to treatment of cells, oligonucleotides were sterilized by filtration through a filter having a pore diameter of 0.20 μm or through a filter having a pore diameter of 0.45 μm (Corning Glass Works, Corning, NY) and stored at -70°C . Oligonucleotide concentrations in solution were determined spectrophotometrically by measuring the ratio of absorbance at 260 nanometers to absorbance at 280 nanometers.

Cell lines

WEHI 164 and H4-IIIC cell lines were purchased from American Type Culture Collection (ATCC, Rockville, MD).

Rat Kupffer cell isolation

5 Kupffer cells were isolated from male rats (300-400 g body weight) by sequential digestion of the rat livers using pronase and type 1 collagenase followed by elutriation, as described (Bautista et al., 1992, Gen. Leukoc. Biol. 51:39-45). Purity of Kupffer cell preparations was assessed by staining the cells for peroxidase activity and assessing the ability of the cells to phagocytose 1 micrometer latex beads (Kamimura et
10 al., 1995, Hepatol. 21:1304-1309). Purity of Kupffer cell preparations exceeded 85% in every experiment described herein. Viability of cells in Kupffer cell preparations was assessed using the Trypan blue exclusion test, and always exceeded 95%.

 Approximately 10^6 Kupffer cells were transferred to individual 35 millimeter diameter dishes, and Kupffer cells were further purified using the adherence
15 method, as described (Kamimura et al., 1995, Hepatol. 21:1304-1309). Cells were typically incubated in RPMI medium with 10% fetal bovine serum for one day following the adherence method procedure, prior to the use of the cells in *in vitro* experiments.

Treatment of Cells with ASO

20 ASOs were suspended in Lipofectamine ® (Life Technologies, Inc., Gaithersburg, MD), a cationic liposome, prior to delivery to cultured rat Kupffer cells, as described (Tu et al., 1995, J. Biol. Chem. 270:28402-28407). Up to 12 µg of an ASO and 8 µg of liposomes were diluted separately in 100 µl of Optimem ® (Life
25 Technologies, Inc., Gaithersburg, MD) reduced serum medium. The two suspensions were gently mixed and the combined suspension was incubated at room temperature for 45 minutes to form oligonucleotide-liposome complexes.

 Kupffer cells were rinsed twice with Optimem® prior to the addition to the cell suspension of a mixture of 800 µl of Optimem® and 200 µl of the combined suspension, which comprised oligonucleotide-liposome complexes. Cells were

exposed to the complexes for 4 hours at 37° C, 5% (v/v) CO₂, and 100% humidity. Antibiotics were not present in the cell culture medium during liposome-mediated delivery.

5 Following treatment with the oligonucleotide-liposome complexes, the medium was removed, and the cells were washed twice with 37°C Optimem® and cultured in RPMI medium with 10% fetal bovine serum for an additional 17 hours. Tumor necrosis factor- α (TNF- α) expression was induced by addition to the cell culture medium of 10 ng/ml of lipopolysaccharide (LPS) for 2 hours. Following LPS treatment, the culture medium was removed and cells were stored at -70° C until TNF- α assays were performed. Cells were rinsed twice with cold phosphate-buffered saline (PBS) and were lysed using a 5% (w/v) SDS solution prior to protein determination.

Extraction of Cellular RNA and Protein

15 Total cellular RNA was prepared from PBS-rinsed cells using Tri Reagent® (Life Technologies, Inc., Gaithersburg, MD) as described (Tu et al., 1995, J. Biol. Chem. 270:28402-28407). RNA concentration was determined by measuring the ratio of absorbance at 260 nanometers to absorbance at 280 nanometers using a Beckman DU-640 spectrophotometer.

20 Total cellular protein was prepared by lysing PBS-rinsed cells using a 5% (w/v) SDS solution at room temperature overnight. Protein concentrations were determined using a MicroBCA protein assay kit (Pierce, Rockford, IL) according to the manufacturer's instruction.

TNF- α Assays

25 TNF- α in cell culture supernatants was assayed by bioassay and ELISA methods. The bioassay was performed as described (Kamimura et al., 1995, Hepatol. 21:1304-1309), using WEHI 164 cells as a assay reactant. ELISA was conducted by using a Cytoscreen KRC3012 ELISA kit (Biosource, Camarillo, CA) according to the manufacturer's specifications. Supernatants containing a high level of TNF- α were diluted prior to assay to ensure reliable assay results. All samples were assayed in triplicate.

Northern Hybridization

Total cellular RNA was isolated as described (Tu et al., 1995, J. Biol. Chem. 270:28402-28407). A Northern blot was prepared using 5 micrograms of total RNA per lane, and was probed using ³²P-labeled cDNA encoding murine TNF- α , as described (Kamimura et al., 1995, Hepatology 22:1304-1309). Densitometric analysis of TNF- α mRNA was standardized by comparison with 18S rRNA hybridization.

Other methods which were used but not described herein are well known and within the competence of one of ordinary skill in the art of antisense technology and molecular biology.

10

Example 1

Screening ASOs Which are Efficacious for Inhibiting TNF- α Expression

Based upon the primary transcript sequence of rat TNF- α (Shirai et al., 1989, Agric. Biol. Chem. 53:1733-1736), seventeen phosphorothioate-modified ASOs were designed which were complementary to different regions of the primary transcript, including the 5'-cap site, the translation initiation codon, various exon/intron junctions, the stop codon, and the 3'-untranslated region, as indicated in Table 2. The ability of each of these ASOs to inhibit expression of rat TNF- α in cultured rat Kupffer cells which were stimulated using bacterial lipopolysaccharide (LPS) was assessed by contacting aliquots of the cells with individual ASOs, culturing the aliquots for about seventeen hours, and then assessing TNF- α expression in the cells.

15

ASOs were delivered into cultured rat Kupffer cells using cationic liposomes (Lipofectamine®, Life Technologies, Inc., Gaithersburg, MD). Cationic liposomes have been demonstrated to enhance cellular uptake and biological activity of phosphorothioate-modified oligonucleotides (Bennett et al., 1992, Mol. Pharmacol. 41:1023-1033; Bennett et al., 1993, J. Liposome Res. 3:85-102; Tu et al., 1995, J. Biol. Chem. 270:28402-28407). Although high concentrations of liposome has been reported to be toxic to some cell lines (Bennett et al., 1992, Mol. Pharmacol. 41:1023-1033), treatment of cultured rat Kupffer cells with 8 μ g/ml Lipofectamine® for 4 hours did not inhibit rat TNF- α expression in Kupffer cells following LPS stimulation.

25

Table 2 summarizes results obtained using ASOs to inhibit rat TNF- α as described herein. Oligonucleotides having the sequence indicated in the table were synthesized and used to treat cultured rat Kupffer cells, as described herein.

Expression of TNF- α protein was assessed following incubation of the cells and

- 5 stimulation using LPS. TNF- α expression is reported in Table 2 as a mean percentage (\pm standard deviation) of TNF- α expression in control cells which were not treated with an ASO. Each ASO in Table 2 is reported using an identifier, a SEQ ID NO, a sequence listing, and an indication of the region of the primary transcript encoding rat TNF- α to which the ASO was designed to be complementary. "Putative tsp" denotes
- 10 an ASO comprising a sequence complementary to the putative transcription-start point. "AUG codon" denotes an ASO comprising a sequence complementary to the translational initiation site. "Ex. #/In. ##" denotes an ASO comprising a sequence complementary to the junction between exon # and intron ## of the RNA molecule encoding rat TNF- α . "3'-Untr. Reg." denotes an ASO comprising a sequence
- 15 complementary to a portion of the 3'-untranslated region of the RNA molecule encoding rat TNF- α . "Activation" denotes TNF- α expression which exceeded TNF- α expression which was observed in control cells.

Table 2

Identifier	SEQ. ID NO:	Oligonucleotide sequence (5' → 3')	Region of primary transcript	TNF- α Prod. (% Con)
5	TJU-0641	1 CCTCGCTGAGTTCTGCCGGCT	putative tsp	97 \pm 8.9
	TJU-0796	2 CCGTGCTCATGGTGTCTTTC	AUG codon	52 \pm 5.7
	TJU-0807	3 GATCATGCTTTCCGTGCTCAT	AUG codon	93 \pm 7.8
	TJU-0981	4 GGCACTCACCTCCTCCTTGTT	Ex. 1/In. 1	94 \pm 7.2
	TJU-1534	5 ACACTTACTGAGTGTGAGGGT	Ex. 2/In. 2	110 \pm 8.5
10	TJU-1730	6 AAACCTACCTACGACGTGGGC	Ex. 3/In. 3	110 \pm 9.7
	TJU-2431	7 GTCGCCTCACAGAGCAATGAC	Ex. 4/STOP	activation
	TJU-2507	38 TAGACGATAAAGGGGTCAGAG	3'-Untr. Reg.	ca. 115
	TJU-2698	8 AGTGAGTTCCGAAAGCCCAT	3'-Untr. Reg.	93 \pm 8.2
	TJU-2719	9 GGCATCGACATTCCGGGGATCC	3'-Untr. Reg.	85 \pm 6.4
15	TJU-2755	10 TGATCCACTCCCCCTCCACT	3'-Untr. Reg.	7.7 \pm 5.1
	TJU-2779	11 CAGCCTTGTGAGCCAGAGGCA	3'-Untr. Reg.	110 \pm 9.4
	TJU-2800	12 GGAGGCCTGAGACATCTTCAG	3'-Untr. Reg.	100 \pm 8.8
	TJU-2819	13 AGGGAAGGAAGGAAGGAAGGG	3'-Untr. Reg.	activation
	TJU-2826	14 CTGAGGGAGGGAAGGAAGGAA	3'-Untr. Reg.	120 \pm 9.8
20	TJU-2840	39 CAGTCTGGGAAGCTCTGAGGG	3'-Untr. Reg.	ca. 115
	TJU-2879	15 GGTTCCGTAAGGAAGGCTGG	3'-Untr. Reg.	93 \pm 7.2
	TJU-2927	16 AATAATAAATAATAATAAAT	3'-Untr. Reg.	99 \pm 8.3
	TJU-2991	17 TTCCCAACGCTGGGTCTCCCA	3'-Untr. Reg.	98 \pm 9.9
	TJU-3050	40 GGGATAGCTGGTAGTTTAG	3'-Untr. Reg.	ca. 100
25	TJU-3260	41 CATTTCTTTTCCAAGCGAAC	3'-Untr. Reg.	ca. 90
	TJU-3428	42 AGGCTCCTGTTTCCGGGGAGA	3'-Untr. Reg.	ca. 120
	TJU-2734	18 CCCCCGATCCACTCAGGCATC	3'-Untr. Reg.	82 \pm 6.7
	TJU-2737	19 ACTCCCCGATCCACTCAGGC	3'-Untr. Reg.	14 \pm 5.3
	TJU-2740	20 TCCACTCCCCCGATCCACTCA	3'-Untr. Reg.	7.9 \pm 4.3
30	TJU-2743	21 CCCTCCACTCCCCCGATCCAC	3'-Untr. Reg.	7.5 \pm 4.6
	TJU-2746	22 CCCCCCTCCACTCCCCCGATC	3'-Untr. Reg.	8.2 \pm 4.7
	TJU-2749	23 ACTCCCCCTCCACTCCCCCG	3'-Untr. Reg.	9.1 \pm 5.4
	TJU-2752	24 TCCACTCCCCCTCCACTCCC	3'-Untr. Reg.	7.9 \pm 4.4
	TJU-2755	25 TGATCCACTCCCCCTCCACT	3'-Untr. Reg.	7.7 \pm 5.1
35	TJU-2758	26 GCCTGATCCACTCCCCCTCC	3'-Untr. Reg.	8.2 \pm 4.2
	TJU-2761	27 GCAGCCTGATCCACTCCCCC	3'-Untr. Reg.	15 \pm 6.2
	TJU-2764	28 GAGGCAGCCTGATCCACTCCC	3'-Untr. Reg.	98 \pm 11
	TJU-2755SS	29 AGTGGAGGGGGGAGTGGATCA		activation
	TJU-2755RD	30 CCCTCACTGCTACCTCACCTC		89 \pm 7.0
40	TJU-2749-19	31 ACTCCCCCTCCACTCCCC	3'-Untr. Reg.	8.6 \pm 4.1
	TJU-2740-18	32 TCCACTCCCCCGATCCAC	3'-Untr. Reg.	7.8 \pm 4.0
	TJU-2755-16	33 TGATCCACTCCCCCT	3'-Untr. Reg.	8.4 \pm 4.3

The first twenty-two ASOs listed in Table 2, most of which were selected randomly, and some (i.e. SEQ ID NOs: 38-42) of which were predicted to be

efficacious using the methods described herein, were each examined for the ability to inhibit TNF- α expression in cultured cells when the ASO was present in the cell culture medium at a concentration of 1 micromolar. Only one of the ASOs, TJU-2755, inhibited the expression of TNF- α by at least 90% compared with control cells. TJU-2755 comprised a sequence complementary to a portion of the 3'-untranslated region of the RNA molecule. Another oligonucleotide, TJU-0796, inhibited TNF- α expression but with an efficacy of only 50%. The remaining oligonucleotides either had no effect on TNF- α expression or actually activated TNF- α expression. As indicated in Figure 1, inhibition of TNF- α expression by TJU-2755 is dose-dependent, and the value of I_{50} , the concentration of TJU-2755 in the culture medium which was necessary to effect 50% inhibition of TNF- α expression, was approximately 0.1 micromolar.

To test the specificity of TJU-2755 inhibition of TNF- α expression, two control oligonucleotides were examined at a concentration of 2 micromolar in the culture medium. A scrambled oligonucleotide, TJU-2755-RD, having the same nucleotide composition as TJU-2755 but in random order, and a sense oligonucleotide TJU-2755-SS, which was complementary to TJU-2755, were assessed for the ability to inhibit TNF- α expression. Neither TJU-2755-RD nor TJU-2755-SS inhibited TNF- α expression in cultured rat Kupffer cells. This result indicated that the inhibitory effect of TJU-2755 on TNF- α expression was markedly dependent on the nucleotide sequence of TJU-2755.

Ten additional oligonucleotides were designed and synthesized, each of which comprised a TCCC motif. The ability of each of these ASOs (SEQ ID NO: 18 through SEQ ID NO: 26 and SEQ ID NO: 28 in Table 2) to inhibit TNF- α expression was assessed as described herein. It was determined that all ASOs which inhibited TNF- α expression by at least about 80% comprised at least one full TCCC motif (Table 2). The data also establish that ASOs comprising a TCCC motif can comprise fewer than twenty-one, and as few as sixteen or fewer, nucleotide residues (e.g. TJU-2749-19, TJU-2740-18 and TJU-2755-16 in Table 2).

Each of the ASOs indicated in Table 2 which inhibited TNF- α expression comprised a TCCC motif and was complementary to an RNA molecule encoding rat TNF- α . This demonstrates that a TNF- α -specific ASO can be designed by designing an ASO including a TCCC motif and flanking TNF- α nucleotide sequence(s). Although only TNF- α -specific ASOs comprising between sixteen and twenty-one nucleotide residues have been described herein, it is clear, given the data presented herein, that TNF- α -specific ASOs may be designed which comprise more than twenty-one or fewer than sixteen nucleotide residues by including a TCCC motif and at least one flanking TNF- α nucleotide sequence in the ASO. Preferably, such ASOs comprise no more than one nucleotide residue which is not complementary to a TNF- α -encoding RNA molecule. The ability of these oligonucleotides to inhibit TNF- α expression may be easily assessed using the screening methods described herein.

A number of mechanisms are known by which ASOs are capable of inhibiting protein expression, including translational arrest, inhibition of RNA processing, and promotion of RNase H-mediated degradation of the RNA component of the RNA-oligonucleotide complex (Crook, 1993, FEBS J. 7:533-539). A DNA-RNA heteroduplex of 4 to 6 nucleotides in length is sufficient to evoke RNase H activity (Kramer et al., 1984, Cell 38:299-307). Bennett et al. (1991, J. Immunol. 152:3530-3540) demonstrated that ASOs inhibited human ICAM-1 and E-selectin gene expression by two distinct mechanisms. Oligonucleotides which were complementary to the 3'-untranslated region of either gene (ISIS 1939, ISIS 2302, and ISIS 4730) reduced the corresponding mRNA levels, which suggested that RNase H-mediated degradation mechanism was responsible for the inhibition of gene expression. Oligonucleotides which were complementary to region around the AUG translation initiation codon (ISIS 1750 and ISIS 2679) did not alter mRNA levels, which suggested that translational arrest was responsible for the inhibition of gene expression.

Example 2

The Presence of the TCCC Motif in Reported Efficacious ASOs

A comprehensive search was conducted using the MEDLINE database, current through September 1997, to identify efficacious ASOs which had been reported in the literature. These sequences were examined to determine whether a higher proportion of the sequences comprised a TCCC motif than would be expected by random occurrence of these motifs.

For this literature search, the following conditions were imposed. Only ASOs selected from among 10 or more ASOs as being effective were included. Only ASOs selected from among ASOs designed to target a broad range of RNA regions were included in the search. ASOs presently in FDA-approved human clinical trials were also included in the search.

A total of 42 ASOs complied with these conditions. A TCCC motif was identified in 20 of these ASOs (48%). The nucleotide sequences of the most effective known ASOs comprising the TCCC motif are listed in Table 3. Chi-square analysis indicates that the probability of one TCCC motif existing by chance in 20 of 42 ASOs is remote ($p < 0.001$; $\chi^2 = 34.8$). By comparison, a VCCC motif (i.e. V is A, G, or C, but not T), the sequence was only found in 5 of the 42 most effective ASO sequences. In only two effective known ASOs was the TCCC motif located at the end of the ASO. Thus, it appears that the TCCC motif should be flanked on both sides by non-TCCC motif nucleotide residues that are complementary to nucleotide sequences which flank the GGGA motif of the corresponding RNA molecule.

In Table 3, 20 of the 42 most efficacious ASOs which have been reported in the literature are listed. Each of these ASOs comprises a TCCC motif. The ASOs are grouped according to the nucleotide residue at the 3'-end of the TCCC motif. For each of the ASOs listed, the identifier used in the reported study is indicated, and the reference number corresponding to the study is listed in parentheses beneath the identifier. A list of citations follows the table. The TCCC motif is underlined in each sequence listing. "mRNA" refers to the region of the corresponding mRNA molecule

to which the indicated ASO reported in the study was complementary, and indicates the species and protein corresponding to the mRNA molecule. Where known, the region of the mRNA molecule to which the indicated ASO was complementary is indicated parenthetically. "3'-UTR" refers to the 3'-untranslated region of the mRNA molecule.

5 "AUG" refers to a region comprising the AUG translation initiation codon of the mRNA molecule. "Stop codon" refers to a region comprising a translation stop codon of the mRNA molecule. "5'-UTR" refers to the 5'-untranslated region of the mRNA molecule. "Efficacy" refers to the approximate degree to which gene expression was inhibited in the study. Where only data corresponding to mRNA levels are reported in

10 the indicated study, "M.E." refers to the oligonucleotide of the study which had the maximum effect. "# tested" refers to the number of oligonucleotides which were compared in the indicated study. "ICAM" means intercellular adhesion molecule. "VCAM" means vascular cell adhesion molecule. "PKC" means protein kinase C. "PAI" means plasminogen activator inhibitor. "NGF" means nerve growth factor.

15 "Xklp" means *Xenopus* kinesin-like protein. HCV means the 5'-untranslated region of HCV.

Table 3

Identifier (Ref. #)	mRNA	Inhibitory Oligonucleotide Sequence (listed 5'-3')	# tested
A. ASOs comprising a TCCC motif, followed by C			
5	OL(1)p53 ¹	Human p53(ORF)	CCTGCT <u>TCCCCC</u> CTGGCTCC hum. trials
	ISIS 1939 ^{2,3}	Human ICAM-1(3'-UTR)	CCCCCACCACCT <u>TCCCCT</u> CTC 45
	GM 1508 ⁴	Human ICAM-1(3'-UTR)	CCCCCACCACCT <u>TCCCCT</u> CTCA 39
	ISIS 4189 ⁵	Murine PKC- α (AUG)	CAGCCATGGT <u>TCCCCC</u> CAAC 20
	ISIS 4730 ²	Human E-selectin(3'-UTR)	<u>TTCCCC</u> CAGATGCACCTGTTT 18
10	ISIS 11300 ⁶	Rat PKC- α (ORF)	GACATCCCTT <u>TCCCCC</u> TCGG 13
	C15 ⁷	1.19CAT (5'-UTR)	GAT <u>TCCCCG</u> GGTACCGA 13
	ISIS 3890 ⁸	Human PKC- α (AUG)	GTCAGCCATGGT <u>TCCCCC</u> CCC 20
	Oligo 7 ⁹	<i>Xenopus</i> Xklp-1	ATGCCCTCATCCT <u>TCCCCC</u> CAT >9
B. ASOs comprising a TCCC motif, followed by A			
15	G 3139 ¹⁰	Human bcl-2 (ORF)	GTTCT <u>TCCC</u> CAGCGTGTGCCAT hum. trials
	GM 1534 ⁴	Human VCAM-1(5'-UTR)	AACCCTTATTTGTGT <u>TCCC</u> ACC 28
	ODN 2309 ¹¹	Murine tPA (5'-UTR)	<u>GTCCCA</u> AAGAGTTGAGGAG 18
	ISIS 3466 ¹²	Human p120 (3'-UTR)	CACCCGCCTTGGCCT <u>TCCC</u> AC 18
C. ASOs comprising a TCCC motif, followed by G			
	ISIS 5132 ¹³	Human <i>C-raf</i>	<u>TCCCGC</u> CTGTGACATGCATT hum. trials
	ISIS 5995 ¹⁴	Human MDR-1 (AUG)	CCAT <u>TCCCG</u> ACCTCGCGCT 32
	T 195 ¹⁵	Human TNF (ORF)	CCACGT <u>TCCCG</u> GATCATGC 15
D. ASOs comprising a TCCC motif, followed by T			
	4484-4503 ¹⁶	Human HIV (SA)	TCTGCTGT <u>TCCCT</u> GTAATAAA 20
	ISIS 3801 ³	Human VCAM	AACCCAGTGCT <u>TCCCT</u> TTTGCT 15
E. ASO comprising a TCCC motif at the 3'-end thereof			
30	ISIS 3522 ¹⁷	Human PKC- α (AUG)	AAAACGTCAGCCATGGT <u>TCCC</u> 20

The references indicated in Table 3 are:

- ¹Bishop et al., 1996, J. Clin. Oncol. 14:1320-1326
- ²Chiang et al., 1991, J. Biol. Chem. 266:18162-18171
- ³Bennett et al., 1994, J. Immunol. 152:3530-3540
- 5 ⁴Lee et al., 1995, Shock 4:1-10
- ⁵Dean et al., 1994, Proc. Natl. Acad. Sci. U.S.A. 91:11762-11766
- ⁶Dean et al., 1996, Biochem. Soc. Trans. 24:623-629
- ⁷Johansson et al., 1994, Nucl. Acids Res. 22:4591-4598
- ⁸Dean et al., 1994, J. Biol. Chem. 269:16146-16424
- 10 ⁹Vermos et al., 1995 Cell 81:117-127.
- ¹⁰Cotter et al., 1994, Oncogene 9:3049-3055
- ¹¹Stutz et al., 1997, Mol. Cell. Biol. 17:1759-1767
- ¹²Perlaky et al., 1993, Anti-cancer Drug Des. 8:3-14
- ¹³Monia et al., 1996, Nature Med. 2:668-675
- 15 ¹⁴Alahari et al., 1996, Mol. Pharmacol. 50:808-819
- ¹⁵d'Hellencourt et al., 1996, Biochim. Biophys. Acta 1317:168-174
- ¹⁶Goodchild et al., 1988, Proc. Natl. Acad. Sci. USA 85:5507-5511
- ¹⁷Dean et al., 1994, J. Biol. Chem. 269:16416-16424

Hence, it is clear that 5'-TCCC-3' is a nucleotide motif which confers
20 surprising efficacy on ASOs which comprise the sequence. Because it is well known in
the art that uridine has nucleotide binding properties analogous to those of thymidine,
one of skill in the art will recognize that T may also be U.

Therefore, it has been demonstrated herein that ASOs which are
efficacious for inhibiting expression of genes comprising a corresponding RNA
25 molecule may be made by selecting an ASO comprising a nucleotide sequence which
comprises a TCCC motif. That is, ASOs which are efficacious for inhibiting
expression of genes comprising a corresponding RNA molecule may be made by
selecting an ASO comprising a nucleotide sequence complementary to a region of the
corresponding RNA molecule, wherein the region comprises a GGGA motif.

Preferably, the TCCC motif is flanked on both sides by nucleotide sequences which are complementary to the corresponding RNA molecule.

It is significant that the efficacy of ASOs which comprise a TCCC motif has been demonstrated in numerous animal species, including rat (described herein), human, mouse, chicken, and toad (each described in studies summarized in Table 3). The skilled artisan will recognize that because no significant difference exists among animals, and particularly between vertebrates, in the ability of an ASO to undergo hybridization in a cell of an animal, the methods and compositions described herein are equally applicable in all animal species.

Example 3

Prospective Design of ASOs Which are Efficacious for Inhibiting TNF- α Expression

In this Example, a series of ASOs were designed to target each of the GGGA motifs identified in an RNA molecule encoding rat TNF- α . Based on the published sequence of the rat TNF- α gene (Shirai et al., 1989, Agric. Biol. Chem. 53:1733-1736), twenty-eight GGGA motifs exist in the region of the primary transcript of this gene which is located on the 5'-side of the AATAAA polyadenylation site and another three GGGA motifs exist in the region of the primary transcript which is located on the 3'-side of that site. These motifs are located in introns 1-3, in exon 4, and in both the 5'- and 3'-untranslated regions. None of the motifs are located in exon 1, exon 2, or exon 3 of the rat TNF- α gene.

The nucleotide sequences of the twenty-five ASOs which were used in this Example are listed in Table 4, which also lists the sequences of ASOs designated TJU-2740 and TJU-2755, which are described elsewhere herein. Among these ASOs, six were designed to be complementary to TNF- α -encoding RNA regions comprising either two flanking GGGA motifs or two GGGA motifs comprising no more than six nucleotide residues interposed therebetween. The other ASOs were designed to be complementary to TNF- α -encoding RNA regions comprising only one GGGA.

Table 4

	Name of ASO	Nucleotide Sequence (5'-3')	SEQ ID NO:	T _m , °C
5	TJU-0656	CTGGT <u>CCCT</u> TTGGTGTCTCGC	43	60.2
	TJU-0675	TTGCTGTTCT <u>CCCT</u> CTGGCT	44	56.3
	TJU-1032	TTCTTGCCCT <u>CCCTCCCT</u> ACT	45	56.3
	TJU-1056	CCTCTTT <u>CCCT</u> TACCCTCCTG	46	56.3
	TJU-1103	GGTCT <u>CCCTCCCA</u> ACTCTCC	47	60.2
10	TJU-1227	CTTCTTCCCTGT <u>CCCT</u> TGGC	48	58.3
	TJU-1271	TATCT <u>CCCT</u> CGTCT <u>CCCA</u> TCT	49	54.4
	TJU-1310	GTTT <u>CCCTCCCA</u> TCT <u>CCCT</u> CC	50	58.3
	TJU-1424	GAAGCCT <u>CCCG</u> CTCTTTGCC	51	60.2
	TJU-1585	AAAGCTTTAAGT <u>CCCC</u> CGCC	52	56.3
15	TJU-1608	CCTATT <u>CCCTTT</u> CCT <u>CCCA</u> AAA	53	52.4
	TJU-1646	CCCTTAGGTTT <u>CCC</u> AGCAAGC	54	56.3
	TJU-1906	CTGGTCTTTCCACGT <u>CCC</u> ATT	55	54.4
	TJU-2161	GCAGCCTTG <u>TCCCT</u> TGAAGAG	56	56.3
	TJU-2287	CTTGAGCTCAGCT <u>CCCT</u> CAGG	57	58.3
20	TJU-2327	GCTGGAAGACTCCT <u>CCC</u> AGGT	58	58.3
	TJU-2350	GCTGAGCAGGT <u>CCCCCT</u> TCTC	59	60.2
	TJU-2561	AGAGCCACAATT <u>CCCTTT</u> CTA	60	50.5
	TJU-2740	TCCACT <u>CCCCCG</u> ATCCACTCA	20	58.3
	TJU-2755	TGATCCACT <u>CCCCCCT</u> CCACT	10	58.3
25	TJU-3004	GCCTGAAGACAGCTT <u>CCCA</u> AC	61	56.3
	TJU-3208	CAGTCACGGCT <u>CCCG</u> TGGG	62	59.7
	TJU-3466	GGGAAAT <u>TCCC</u> AGGACCAGGG	63	58.3
	TJU-3484	ATTTGGAAT <u>TCCC</u> AGAGTGGG	64	52.4
	TJU-3499	ACTTT <u>TCCC</u> AGCAGGTATTTGG	65	52.4

The ability of the ASOs described in this Example to inhibit TNF- α expression was assessed as described herein using an ASO concentration of 1 micromolar. As indicated in Figure 2, more than half (13/22) of the ASOs described in this Example inhibited TNF- α expression by 75% or more. Seven of the ASOs described in this Example did not significantly inhibit TNF- α expression, including all three of the ASOs designed to be complementary to a GGGA motif located on the 3'-side of the AATAAA polyadenylation site of TNF- α -encoding RNA.

The effect of the presence of several of the ASOs described in this Example on the steady-state level of mRNA encoding TNF- α was assessed by Northern analysis of RNA obtained from cells cultured in the presence of these ASOs. The results of these Northern analyses are summarized in Figure 3. It is evident in Figure 3 that levels of mRNA encoding TNF- α were depressed in cells which were cultured in the presence of ASOs which inhibited expression of TNF- α (i.e. lanes 4, 5, and 7, corresponding to cells cultured in the presence of TJU-2755, TJU-1906, and TJU-3004, respectively). Levels of 18S RNA were unaffected.

Without wishing to be bound by any particular theory, it is hypothesized that these results indicate that inhibition of TNF- α expression by these ASOs occurs by a mechanism which promotes degradation of RNA molecules encoding TNF- α . The fact that TNF- α -inhibitory ASOs were complementary to regions of the primary transcript comprising a GGGA motif suggests that the expression-inhibiting effect is exerted in the nucleus, before the primary transcript is spliced. This hypothesis is consistent with reports that ASOs rapidly accumulate in the nucleus after being introduced directly into the cell cytoplasm by microinjection, electroporation, streptolysin O treatment, or cationic liposome delivery (Giles et al., 1995, Antisense Res. Dev. 5:23-31).

Therefore, while remaining not bound by any particular theory of operation, it is hypothesized that ASOs, RNases and newly synthesized RNA molecules are present in the nucleus following delivery of an ASO to a cell. The nucleus is the primary site at which ASOs exert their gene-expression-inhibiting effect.

The primary transcript of the expression-inhibited gene is the physiological target with which the ASO interacts, rather than the mature mRNA corresponding to that gene. It may be that the mechanism by which an ASO effects primary transcript degradation involves a nuclear RNase.

5 According to this hypothesis, RNA regions comprising an GGGA motif may be preferred sites for RNase digestion. This hypothesis is supported by the observations of Lima and Crooke (1997, Biochemistry 36:390-398), which indicated that although RNase H was not highly specificity with regard to the nucleotide sequence of the DNA-RNA hybrid on which it acts, it preferentially bound to the A-
10 form of a DNA-RNA duplex. Since RNA sequences containing high purine content are predicted to stack in the A-form conformation (Ratmeyer et al., 1994, Biochemistry 33:5298-5304), RNase H activity may be improved using ASOs containing pyrimidine-rich sequences (i.e. which are complementary to RNA molecules which have purine-rich sequences and which therefore are likely to assume the A-form conformation). As
15 can be ascertained by reviewing the nucleotide sequences listed in Table 4, both the TCCC motif itself and the bases at either end of the motif are pyrimidine-rich in the most potent ASOs.

 This hypothesis may help explain why many ASOs designed by others were not efficacious. Most of ASOs reported in the literature were designed to target a
20 region of a mature mRNA molecule, rather than a region of the corresponding primary transcript. For example, about 70% of reported ASOs were designed to target the mRNA region comprising the AUG codon. Were these ASOs instead designed to be complementary to a region of the primary transcript, particularly a region comprising a GGGA motif as described herein, these ASOs might have been more efficacious.

25 The experiments described in this Example demonstrate that, in contrast to empirical screening, designing ASOs by targeting the fragments comprising a GGGA motif, as described in this Example, is much more likely to yield ASO sequences which are efficacious for inhibiting expression of a gene product.

Example 4ASOs Which are Efficacious forInhibiting Expression of Proteins Other than TNF- α

5 The inventors have used the strategy described herein to design ASOs which were efficacious for inhibiting expression of genes other than TNF- α . By way of example, a successful design of ASOs efficacious to inhibit expression of rat inducible nitric oxide synthase was described by Cao et al. (1998, Alcoholism Clin. Exp. Res. 22:108a).

10 The disclosures of each and every patent, patent application and publication cited herein are hereby incorporated herein by reference in their entirety.

While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all
15 such embodiments and equivalent variations.

What is claimed is:

1. An antisense oligonucleotide for inhibiting expression of a gene which encodes TNF- α in an animal, said oligonucleotide comprising from 12 to 50 nucleotide residues, wherein at least 90% of the nucleotide residues of said oligonucleotide are complementary to a region of an RNA molecule which corresponds to said gene, wherein said region comprises a GGGA motif.

2. The antisense oligonucleotide of claim 1, wherein said oligonucleotide comprises from 14 to 30 nucleotide residues, wherein said oligonucleotide comprises a TCCC motif, and wherein at least 95% of the nucleotide residues of said oligonucleotide are complementary to said region.

3. The antisense oligonucleotide of claim 1, wherein said oligonucleotide comprises from 16 to 21 nucleotide residues, comprises a TCCC motif, and is completely complementary to said region.

4. The antisense oligonucleotide of claim 1, wherein said oligonucleotide has a nucleotide sequence selected from the group consisting of SEQ ID NOs: 19-27, SEQ ID NOs: 31-33, SEQ ID NOs: 44-55, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 60, and SEQ ID NO: 61.

5. The antisense oligonucleotide of claim 1, wherein said animal is a human.

6. The antisense oligonucleotide of claim 5, wherein said antisense oligonucleotide is complementary to from 12 to 50 consecutive nucleotide residues of a region of the human TNF- α gene selected from the group consisting of regions I - XXII, said antisense oligonucleotide being complementary to at least one GGGA motif in said region.

7. A method of making an antisense oligonucleotide for inhibiting expression of a gene in an animal, said method comprising

identifying an RNA molecule corresponding to said gene, wherein said RNA molecule comprises a GGGA motif; and

synthesizing an oligonucleotide complementary to at least a portion of said RNA molecule, said portion comprising said motif, whereby said oligonucleotide is efficacious for inhibiting said gene.

8. The method of claim 7, wherein at least a portion of said oligonucleotide comprises a randomly-generated sequence.

9. The method of claim 7, wherein said gene is a human gene.

10. The method of claim 7, wherein said RNA molecule is the primary transcript of said gene.

11. An antisense oligonucleotide made by the method of claim 7.

12. A method of treating an animal afflicted with a disease or disorder characterized by the presence in an affected cell of said animal of an RNA molecule which corresponds to a gene, which RNA molecule comprises a region comprising a GGGA motif, said method comprising

providing an antisense oligonucleotide which is at least 90% complementary to said region; and

administering said oligonucleotide to said animal.

13. The method of claim 12, wherein said antisense oligonucleotide is completely complementary to said region.

14. The method of claim 12, wherein said RNA molecule is the primary transcript of said gene.

15. The method of claim 12, wherein said animal is a human.

16. The method of claim 15, wherein said gene encodes human TNF- α .

17. The method of claim 12, wherein at least one linkage between nucleotide residues of said oligonucleotide is a phosphorothioate linkage.

18. A method of inhibiting expression of a gene in an animal cell, said method comprising administering to said cell an antisense oligonucleotide which is complementary to a region of an RNA molecule corresponding to said gene, wherein said region comprises a GGGA motif.


19. A method of predicting the efficacy of an antisense oligonucleotide for inhibiting expression of a gene, said method comprising determining whether said antisense oligonucleotide is complementary to a region of an RNA molecule corresponding to said gene, wherein said region comprises a GGGA motif, whereby complementarity of said antisense oligonucleotide to said portion is an indication that said antisense oligonucleotide is efficacious for inhibiting expression of said gene.

20. A method of separating from a mixture of oligonucleotides an antisense oligonucleotide which is efficacious for inhibiting expression of a gene, said method comprising


contacting said mixture with a support linked to an oligonucleotide comprising a GGGA motif, whereby said efficacious antisense oligonucleotide associates with said support; and

separating said support from said mixture.

1/5



2/5



3/5

	1	2	3	4	5	6	7	8	9
Name of ASO	-	-	0796	2755	1906	2350	3004	3208	3466
Motif containing	-	-	No	Yes	Yes	Yes	Yes	Yes	Yes
LPS stimulation	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
TNF- α inhibition	-	-	48%	92%	80%	18%	77%	8%	No

TNF- α mRNA

18S rRNA

Fig. 3

4/5

Fig. 4 (Sheet 1 of 2)

```

1  gaattccggg  tgatttcaact  cccggctgtc  caggcttgtc  ctgctacccc
51  acccagcctt  tcctgaggcc  tcaagcctgc  caccaagccc  ccagctcctt
101 ctccccgcag  gacccaaaca  caggcctcag  gactcaacac  agcttttccc
151 tccaacccgt  tttctctccc  tcaacggact  cagctttctg  aagccccctc
201 cagttctagt  tctatctttt  tcctgcatcc  tgtctggaag  ttagaaggaa
251 acagaccaca  gacctggtcc  ccaaaagaaa  tggaggcaat  aggtttttgag
301 gggcatgGGG Acgggggttca gcctccaggg  tcctacacac  aaatcagtca
351 gtggcccaga agacccccct cggaatcggg  gcaGGGAgga tgGGGAggtg
401 gaggggtatc cttgatgctt  gtgtgtcccc  aactttccaa  atccccgccc
451 ccgcgatgga  gaagaaaccg  agacagaagg  tgcaggggccc  actaccgctt
501 cctccagatg  agctcatggg  tttctccacc  aaggaagttt  tccgctgggt
551 gaatgattct  ttccccgccc  tcctctcgcc  ccaGGGACat ataaaggcag
601 ttgttggcac  acccagccag  cagacgctcc  ctcagcaagg  acagcagagg
651 accagctaag aGGGAgagaa gcaactacag  acccccctg  aaaacaaccc
701 tcagacgcca  catcccctga  caagctgcca  ggcaggttct  ctctctctca
751 catactgacc  cacggcttca  ccctctctcc  cctggaaagg  acaccatgag
801 cactgaaagc atgatccGGG Acgtggagct  ggccgaggag  gcgctcccca
851 agaagacagg  gggggccccag  ggctccaggc  ggtgcttggt  cctcagcctc
901 ttctccttcc  tgatcgtggc  aggcgccacc  acgctcttct  gcctgctgca
951 ctttgaggatg  atcgcccccc agaGGGAaga  ggtgagtgcc  tggccagcct
1001 tcattccactc tcccacccaa gGGGAaatga  gagacgcaag agaGGGAgag
1051 agatGGGATg ggtgaaagat gtgcgctgat  aGGGAGGGAT gagagagaaa
1101 aaaacatgga gaaagacgGG GAtgcagaaa  gagatgtggc  aagagatgGG
1151 GAagagagag agagaaagat  ggagagacag  gatgtctggc  acatggaagg
1201 tgctcactaa  gtgtgtatgg  agtgaatgaa  tgaatgaatg  aatgaacaag
1251 cagatatata  aataagatat  ggagacagat  gtgggggtgtg agaagagaga
1301 tggGGGAaga aacaagtgat atgaataaag  atggtgagac agaaagagcG
1351 GGAaatatga cagctaagga  gagagatggg  ggagataaagg  agagaagaag
1401 ataggggtgtc tggcacacag aagacactca  GGGAaagagc tgttgaatgc
1451 tgggaaggtga  atacacagat  gaatggagag  agaaaaccag  acacctcagg
1501 gctaagagcg  caggccagac  aggcagccag  ctgttcctcc  tttaagggtg
1551 actccctcga  tgttaaccat  tctccttctc cccaacagtt  ccccaGGGAC
1601 ctctctctaa tcagccctct  ggcccaggca  gtcagtaagt  gtctccaaac
1651 ctctttccta  attctgggtt  tgggtttggg  ggtagggtta  gtaccgggtat
1701 ggaagcagtg gGGGAaat  aaagttttgg  tcttggGGGA ggatggatgg
1751 aggtgaaagt  aggggggtat  tttctaggaa  gtttaagggt  ctgagctttt

```

5/5

Fig. 4 (Sheet 2 of 2)

```

1801 tctttttctct ctctctcttca ggatcatctt ctccaacccc gagtgacaag
1851 cctgtagccc atgtttagg taagagctct gaggatgtgt cttggaactt
1901 ggaggggctag gatttgGGGA ttgaagcccc gctgatggta ggcagaactt
1951 ggagacaatg tgagaaggac tccctgagct caaGGGAagg gtggagggaac
2001 agcacaggcc ttagtGGGAt actcagaacg tcatggccag gtGGGAtgtG
2051 GGAtgacaga cagagaggac aggaaccgga tgtgggggtgg gcagagctcg
2101 agggccagga tgtggagagt gaaccgacat ggccacactg actctcctct
2151 ccctctctcc ctccctccag caaacctca agctgagggg cagctccagt
2201 ggctgaaccg ccgggccaat gccctcctgg ccaatggcgt ggagctgaga
2251 gataaccagc tgggtggtgcc atcagagggc ctgtacctca tctactccca
2301 ggtcctcttc aaggggccaag gctgcccctc caccatgtg ctctcacc
2351 acaccatcag ccgcctcgc gtctcctacc agaccaaggt caacctcctc
2401 tctgccatca agagcccctg ccagaGGGA acccagagg gggctgaggc
2451 caagccctgg tatgagccca tctatctGGG Aggggtcttc cagctggaga
2501 agggtgaccg actcagcgt gagatcaatc ggcccgacta tctcgacttt
2551 gccgagtctg ggcaggctca ctttGGGAtc attgccctgt gaggaggacg
2601 aacatccaac ctccccaac gcctcccctg cccaatccc tttattacc
2651 cctccttcag acaccctcaa cctcttctgg ctcaaaaaga gaattggggg
2701 cttagggtcg gaaccaagc ttagaacttt aagcaacaag accaccactt
2751 cgaaacctgg gattcaggaa tgtgtggcct gcacagtga gtgctggcaa
2801 ccactaagaa ttcaaactgg ggcctccaga actcactggg gcctacagct
2851 ttgatecctg acatctggaa tctggagacc aGGGAgcctt tggttctggc
2901 cagaatgctg caggacttga gaagacctca cctagaaatt gacacaagtg
2951 gaccttaggc ctctctctct ccagatgttt ccagacttcc ttgagacacg
3001 gagcccagcc ctcccatgg agccagctcc ctctatttat gtttgactt
3051 gtgattattt attatttatt tattatttat ttatttacag atgaatgtat
3101 ttattttGGGA gaccggggta tcctggGGGA cccaatgtag gagctgcctt
3151 ggctcagaca tgttttccgt gaaaacggag ctgaacaata ggctgttccc
3201 atgtagcccc ctggcctctg tgccttcttt tgattatgtt ttttaaata
3251 tttatctgat taagttgtct aaacaatgct gatttgggtga ccaactgtca
3301 ctcatgtctg agcctctgct ccccagGGGA gttgtgtctg taatcgccct
3351 actattcagt ggcgagaaat aaagtttgct tagaaaagaa acatggtctc
3401 cttcttgga ttaattctgc atctgcctct tcttgtgggt GGGAagaagc
3451 tcctaagtc ctctctccac aggtttaaag atccctcgga ccagtcacca
3501 tccttagact cctagggccc tggagaccct acataaacia agcccaacag
3551 aatattcccc atccccagg aaacaagagc ctgaacctaa ttacctctcc
3601 ctcagggcat GGGAatttcc aactctGGGA attc

```

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/13711

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/70; C07H 21/00; C12P 19/34

US CL :435/91.5; 514/44; 536/24.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/91.5; 514/44; 536/24.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN: Medline Biosis Embase CAPlus WPIDS

APS

Search terms: TNF-alpha, antisense, oligonucleotide

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,616,490 A (SULLIVAN et al.) 01 April 1997, columns 3-6.	1-17
Y	MITSUHASHI, M. Strategy for designing specific antisense oligonucleotide sequences. J. Gastroenterol. April 1997, Vol. 32, No. 2, pages 282-287, see entire document.	1-17
Y	PENNICA et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 20 December 1984, Vol. 312, No. 5996, pages 724-729, see entire document.	1-17

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
*A	document defining the general state of the art which is not considered to be of particular relevance		
*B	earlier document published on or after the international filing date	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O	document referring to an oral disclosure, use, exhibition or other means		
*P	document published prior to the international filing date but later than the priority date claimed	*A	document member of the same patent family

Date of the actual completion of the international search

01 OCTOBER 1998

Date of mailing of the international search report

22 OCT 1998

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ROBERT SCHWARTZMAN

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/13711

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	BRANCH, A.D. A good antisense molecule is hard to find. Trends Biol. Sci. February 1998, Vol. 23, No. 2, pages 45-50, see entire document.	1-17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/13711

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-17

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/13711

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-17, drawn to antisense oligonucleotides (ASO), wherein at least 90% of said ASO are complementary to a region of an RNA molecule, said region comprising a GGGA motif; methods of making said ASO, and methods of treating a disease or disorder in an animal by administering said ASO.

Group II, claim(s) 18, drawn to methods of inhibiting expression of a gene in an animal cell by administering an ASO that is complementary to an mRNA region comprising a GGGA motif.

Group III, claim(s) 19, drawn to methods of predicting the efficacy of an ON for inhibiting expression of a gene by determining if said ASO is complementary to a GGGA motif in the gene.

Group IV, claim 20, drawn to a method of separating an ASO from a mixture of oligonucleotide, wherein said mixture contacts an oligonucleotide that is associated with a support, and wherein said oligonucleotide comprises a GGGA motif.

The inventions listed as Groups I-IV lack unity of invention because, under 37 CFR 1.475(b):

(b) An international or a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:

....
(3) A product, a process specially adapted for the manufacture of said product, and a use of the said product;
..

....
(c) If an application contains claims to more or less than one of the combinations of categories of invention set forth in paragraph (b) of this section, unity of invention might not be present.

(d) If multiple products, processes of manufacture, or uses are claimed, the first invention of the category first mentioned in the claims of the application and the first recited invention of each of the other categories related thereto will be considered as the main invention in the claims. See PCT Article 17(3)(a) and 1.476(c).

In the instant application, Group I contains claims 1-17, which are drawn to a product (claims 1-6), a process specially adapted for the manufacture of said product (claims 7-11), and a use of the said product (claims 12-17). See 37 CFR 1.475(b)(3). However, Groups II-IV, each containing one independent claim (claims 18, 19, and 20, respectively), are each drawn to methods that are not the first invention of the category first mentioned in the claims or the first recited invention of each of the other categories related thereto, so that each of Groups II-IV cannot be considered as the main invention of the claims. See 37 CFR 1.475(d). Therefore, a determination that the instant application lacks unity of invention, is proper.

PCT Rules 13.1 and 13.2 do not provide for multiple distinct products and methods within a general inventive concept. Note PCT Article 17(3)(a).